Adam Bass, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Esophageal cancers
- Stomach (gastric) cancer
My Specialties
- Targeted therapy
- Immunotherapy
Get to Know Me
I’m a medical oncologist and physician scientist who cares for people with gastrointestinal cancers such as esophageal cancer and stomach (gastric) cancer.
I see patients at the Rockefeller Outpatient Pavilion at Memorial Sloan Kettering Cancer Center (MSK).
I also lead research on gastrointestinal cancer biology and creating new cancer therapies. We are in an era with great potential to connect scientific discoveries and new technologies to develop new treatments for our patients. While this is far from easy, I am confident that we are on the path to meaningful impact.
Caring for those with cancer is not just a privilege, it also motivates me as a scientist to focus my work on my patients’ most important needs. Managing a cancer diagnosis is both a scientific and personal challenge. As a scientist, I work to understand the biology of these diseases and how we can use this knowledge to develop better treatments.
At the same time, I know how cancer can affect each person and their family. As a physician, I aim to provide the best and most compassionate care for patients during a difficult time in their lives. My combined role as a scientist and physician helps me to do what is best for each person.
Outside of work, I enjoy spending time with my wife, two teenage sons, and our somewhat eccentric rescue dog. We love to travel and explore places and food from not just around the world but also the neighborhoods of New York City and towns in the Hudson valley. I am currently managing a borderline unhealthy obsession with the New York Times puzzles.
I'm a gastrointestinal (GAS-troh-in-TES-tih-nul) medical oncologist, which is a cancer doctor who specializes in gastrointestinal (GI) cancers. This includes anal, colorectal, esophageal, gastric (stomach), liver, and pancreatic cancers. We also treat GI stromal tumors and neuroendocrine tumors.
- Attending Physician
- Physician-Scientist
Conditions I Treat
- Esophageal cancers
- Stomach (gastric) cancer
My Specialties
- Targeted therapy
- Immunotherapy
Education
- MD, Duke University
Residencies
- Internal Medicine, Massachusetts General Hospital
Fellowships
- Medical Oncology, Dana-Farber Cancer Institute
Board Certifications
- Medical Oncology
Awards and Honors
- Inducted into American Association of Physicians (2022)
- Team Science Award, American Association for Cancer Research (2020)
- Discovery Award, Dana-Farber Cancer Institute (2017)
- Inducted into American Society for Clinical Investigation (2017)
- Eugene D. O'Kelly Award, American Cancer Society (2016)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
HMO, EPO PPO, POS, Transplant
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
POS, HMO
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO
This is a dual payer plan, which means 2 health insurance companies share this plan. MSK providers are out-of-network with UnitedHealthcare.
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
This plan is in-network at our New York sites only.
In Network Coverage Type
HMO, PPO
In Network Coverage Type
PPO EPO
In Network Coverage Type
HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
EPO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
PPO, HMO
Your plan may not cover visits to our New York sites. Please call the number on the back of your insurance card to see what your health plan covers.
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, POS, EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO (City Employee Health Plans Gold and Gold Care Only)
In Network Coverage Type
Supplemental
In Network Coverage Type
PPO/OAP
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
TBD
In Network Coverage Type
PPO, EPO
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
This plan is in-network at our New York sites only.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO, POS
In Network Coverage Type
PPO, POS, HMO
In Network Coverage Type
State Government
Learn more about the insurance plans that participate with MSK.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
Health plans can change at any time. Call the number on the back of your insurance card to see what your plan covers. Make sure it covers the MSK location where you’ll get care.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, Papageorge AG, Stachler MD, Liao J, Zhou J, Wu Z, Akarca FG, de Klerk LK, Derks S, Pierobon M, Hoadley KA, Wang TC, Church G, Wong KK, Petricoin EF, Cox AD, Lowy DR, Der CJ, Bass AJ*. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer discovery. 2020;10(2):288-305. Epub 2019/11/28. CD-19-0811. PubMed PMID: 31771969; PMCID: PMC7007383.
Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, Gonzalez A, McPartlan JS, Li T, Zhang Y, Bin Liu J, Lazaro JB, Gu P, Piett CG, Apffel A, Ali SO, Deasy R, Keskula P, Ng RWS, Roberts EA, Reznichenko E, Leung L, Alimova M, Schenone M, Islam M, Maruvka YE, Liu Y, Roper J, Raghavan S, Giannakis M, Tseng YY, Nagel ZD, D’Andrea A, Root DE, Boehm JS, Getz G, Chang S, Golub TR, Tsherniak A, Vazquez F, Bass AJ*. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. 2019;568(7753):551-6. Nature. Epub 2019/04/12. PubMed PMID: 30971823; PMCID: PMC6580861.
Liu, Y, Sethi, NS, Hinoue T, Schneider BG, Cherniack, AD, Sanchez-Vega F, Seoanoe JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Kanchi RS, Rabkin CS, Willis JE, Wang KK, McCall SJ, Mishra L, Ojesina AI, Bullman S, Pedamallu CS, Lazar AJ, Sakai R, The Cancer Genome Atlas Netowrk, Thorsson V, Bass AJ*, Laird PW. Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell, 2018 Apr 9;33(4):721-735
Pectasides, E., Stachler, M. D., Derks, S., Liu, Y., Maron, S., Islam, M., Alpert, L., Kwak, H., Kindler, H., Polite, B., Sharma, M. R., Allen, K., O’Day, E., Lomnicki, S., Maranto, M., Kanteti, R., Fitzpatrick, C., Weber, C., Setia, N., Xiao, S. Y., Hart, J., Nagy, R., Kim, K. M., Choi, M. G., Min, B. H., Nason, K. S., O’Keefe, L., Watanabe, M., Baba, H., Lanman, R., Agoston, A. T., Oh, D. J., Dunford, A., Thorner, A. R., Ducar, M. D., Wollison, B. M., Coleman, H. A., Ji, Y., Posner, M. C., Roggin, K. K., Turaga, K., Chang, P., Hogarth, K., Siddiqui, U., Gelrud, A., Ha, G., Freeman, S. S., Rhoades, J., Reed, S., Gydush, G., Rotem, D., Davison, J., Imamura, Y., Adalsteinsson, V., Lee, J., Bass, A. J.* and Catenacci, D. V. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discovery. 2017. doi: 10.1158/2159-8290.CD-17-0395. PubMed PMID: 28978556
TCGA Consortium.* Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Nature, 2014 Sep 11;513(7517):202-9 (*Sole Corresponding Author)
Visit PubMed for a full listing of Dr. Bass’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.
MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.
Adam Bass discloses the following relationships and financial interests:
-
Curie.Bio
Professional Services and Activities -
Dana Farber
Intellectual Property Rights -
Earli Inc.
Equity; Professional Services and Activities (Uncompensated) -
Helix Nanotechnologies, Inc.
Equity
-
Novartis
Professional Services and Activities (Uncompensated) -
Signet Therapeutics
Equity; Professional Services and Activities -
Stipple Bio
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2025 through disclosure submission in spring 2026). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].